ReviewMaterials today. Bio2025
Poloxamer-based drug delivery systems: Frontiers for treatment of solid tumors.
Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Plant-Derived Thylakoids Potentiate Copper-Mediated Multimodal Cell Death via Hypoxia Alleviation for Synergistic Antitumor Therapy.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Influence of Excipients on the Release Kinetics and Antioxidant Activity of Encapsulated Propolis Phenolic Compounds.Antioxidants (Basel, Switzerland) · 2026Article
- Stepwise effects of formulation additives and process parameters on ethanol injection-prepared nanoliposomes for cancer delivery: a preformulation study.Scientific reports · 2026Article
- Dual-Stimuli Injectable Platforms for Localized Breast Cancer Therapy.Nano letters · 2026Review
- Metformin potentiates DSF/Cu-loaded pluronic nanoparticles to improve therapeutic efficacy in triple-negative breast cancer.BMC biotechnology · 2026Article
- Innovations in the Delivery of Bioactive Compounds for Cancer Prevention and Therapy: Advances, Challenges, and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Engineered pluronic nanomicelles containing ATRA and sodium butyrate for selective TNBC differentiation therapy.Medical oncology (Northwood, London, England) · 2025Article
- Influence of Polymers Diversity on the Dissolution Kinetics of EncapsulatedGels (Basel, Switzerland) · 2025Article
- Ultrasonic-Responsive Pluronic P105/F127 Nanogels for Overcoming Multidrug Resistance in Cancer.Gels (Basel, Switzerland) · 2025Article
- Development and Characterization of Citalopram-Loaded Thermosensitive Polymeric Micelles for Nasal Administration.Pharmaceutics · 2025Article
- Dual-loaded niosome-dendrimer nanoplatform enhances Tirapazamine delivery to hypoxic breast cancer cells.Scientific reports · 2025Article
- Advancements in Hydrogels: A Comprehensive Review of Natural and Synthetic Innovations for Biomedical Applications.Polymers · 2025Review
- Tumor Microenvironment Responsive TPZ-Loaded Core-Shell Polymeric Nanoparticles for Selective Cancer Bioreductive Therapy.Advanced pharmaceutical bulletin · 2025Article
- Hyaluronic acid-modified theranostic niosomes for targeted Fingolimod delivery and inhibition of triple-negative breast cancer metastasis.Medical oncology (Northwood, London, England) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pluronics or poloxamers are a type of triblock copolymer. These non-ionic molecules consist of a hydrophobic block embedded in two hydrophilic parts. Pluronics have become favorite materials for use in the field of biomedical research due to having favorable physicochemical and biological properties such as amphiphilicity, solubility in ionic and non-ionic solutions, biocompatibility, biodegradability, self-assembly and low toxicity. The scope of these applications can vary from tissue engineering to drug delivery. One of the important uses of pluronics is to deliver drugs to various cancer cells. Herein we first provide an overview on variety of ploronic biomaterials. And then intensively evaluate their potential as drug delivery systems (DDSs) for treatment of solid tumors with special focus on breast cancers. After explaining the pros and cons of pluronics, the current status in clinical settings and future prospects are highlighted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.